CNS Pharmaceuticals annual free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
CNS Pharmaceuticals Free Cash Flow (FCF) History (CNSP)
CNS Pharmaceuticals reported −$13.8M in free cash flow for fiscal 2025, an increase of $3.3M from the previous fiscal year.
View full CNS Pharmaceuticals company overviewCNS Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$13.8M | $3.3M | — | — |
| 2024 | 2024-12-31 | −$17.1M | −$3.0M | — | — |
| 2023 | 2023-12-31 | −$14.1M | −$3.6M | — | — |
| 2022 | 2022-12-31 | −$10.6M | $3.0M | — | — |
| 2021 | 2021-12-31 | −$13.5M | −$6.2M | — | — |
| 2020 | 2020-12-31 | −$7.3M | −$3.8M | — | — |
| 2019 | 2019-12-31 | −$3.6M | −$2.9M | — | — |
| 2018 | 2018-12-31 | −$716,385 | — | — | — |
CNS Pharmaceuticals quarterly free cash flow
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q3.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.5M | −$165,140 | — | — |
| Q1 2026 | 2026-03-31 | −$4.7M | −$2.3M | — | — |
| Q2 2025 | 2025-06-30 | −$5.3M | −$3.5M | — | — |
| Q1 2025 | 2025-03-31 | −$3.2M | $123,536 | — | — |
| Q3 2023 | 2023-09-30 | −$3.4M | −$300,864 | — | — |
| Q4 2022 | 2022-12-31 | −$2.3M | $933,554 | — | — |
| Q3 2022 | 2022-09-30 | −$1.8M | $181,242 | — | — |
| Q2 2022 | 2022-06-30 | −$3.4M | $1.6M | — | — |
| Q1 2022 | 2022-03-31 | −$3.1M | $234,526 | — | — |
| Q4 2021 | 2021-12-31 | −$3.2M | −$1.8M | — | — |
| Q3 2021 | 2021-09-30 | −$2.0M | −$721,842 | — | — |
| Q2 2021 | 2021-06-30 | −$5.0M | −$2.2M | — | — |
| Q1 2021 | 2021-03-31 | −$3.3M | −$1.5M | — | — |
| Q4 2020 | 2020-12-31 | −$1.4M | $1.0M | — | — |
| Q3 2020 | 2020-09-30 | −$1.3M | −$895,354 | — | — |
| Q2 2020 | 2020-06-30 | −$2.8M | −$2.1M | — | — |
| Q1 2020 | 2020-03-31 | −$1.9M | −$1.8M | — | — |
| Q4 2019 | 2019-12-31 | −$2.5M | — | — | — |
| Q3 2019 | 2019-09-30 | −$378,319 | — | — | — |
| Q2 2019 | 2019-06-30 | −$625,262 | — | — | — |
| Q1 2019 | 2019-03-31 | −$82,688 | — | — | — |
CNS Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$7.3M to −$13.8M, a net decrease of $6.5M. CNS Pharmaceuticals's latest reported quarter, Q2 2026, generated −$3.5M in free cash flow, a decrease of $165,140 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review CNS Pharmaceuticals filings at SEC.gov ↗